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A B S T R A C T 
Objectives: To compare the pregnancy outcome 
of the fluorescent in-situ hybridisation and 
array comparative genomic hybridisation in 
preimplantation genetic diagnosis of translocation 
carriers.
Design: Historical cohort.
Setting: A teaching hospital in Hong Kong.
Patients: All preimplantation genetic diagnosis 
treatment cycles performed for translocation 
carriers from 2001 to 2013. 
Results: Overall, 101 treatment cycles for 
preimplantation genetic diagnosis in translocation 
were included: 77 cycles for reciprocal translocation 
and 24 cycles for Robertsonian translocation. 
Fluorescent in-situ hybridisation and array 
comparative genomic hybridisation were used in 78 
and 11 cycles, respectively. The ongoing pregnancy 
rate per initiated cycle after array comparative 
genomic hybridisation was significantly higher 
than that after fluorescent in-situ hybridisation in 
all translocation carriers (36.4% vs 9.0%; P=0.010). 
The miscarriage rate was comparable with both 
techniques. The testing method (array comparative 
genomic hybridisation or fluorescent in-situ 
hybridisation) was the only significant factor affecting 
Comparison between fluorescent in-situ 
hybridisation and array comparative genomic 
hybridisation in preimplantation genetic 
diagnosis in translocation carriers
Introduction
Since the report of first live-birth after 
preimplantation genetic diagnosis (PGD) published 
in 1990,1 more than 21 000 cycles have been 
performed worldwide, based on the data from 
ESHRE (European Society of Human Reproduction 
and Embryology) PGD consortium in the past two 
New knowledge added by this study
• Fluorescence in-situ hybridisation (FISH) has been widely used in preimplantation genetic diagnosis (PGD) in 
translocation carriers. However, array comparative genomic hybridisation (aCGH) has largely replaced FISH 
since its development due to the advantages of testing all 24 chromosomes and improved pregnancy rates. 
This is the first study to show the use of aCGH in Hong Kong. Compared with FISH, aCGH was associated 
with significantly higher rate of ongoing pregnancy in translocation carriers (both reciprocal and Robertsonian 
translocations). 
Implications for clinical practice or policy
• Array CGH should be the technique of choice for PGD in translocation carriers.
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decades.2 Fluorescent in-situ hybridisation (FISH) 
has been used for PGD in translocation carriers. This 
technique uses chromosome-specific DNA probes in 
metaphase chromosomes or interphase nuclei. For 
PGD in translocation carriers, the usual approach 
is to use commercially available centromeric, locus-
specific and subtelomeric probes depending on the 
translocated segments.3 
ORIGINAL ARTICLE
the ongoing pregnancy rate after controlling for 
the women’s age, type of translocation, and clinical 
information of the preimplantation genetic diagnosis 
cycles by logistic regression (odds ratio=1.875; 
P=0.023; 95% confidence interval, 1.090-3.226).
Conclusion: This local retrospective study confirmed 
that comparative genomic hybridisation is associated 
with significantly higher pregnancy rates versus 
fluorescent in-situ hybridisation in translocation 
carriers. Array comparative genomic hybridisation 
should be the technique of choice in preimplantation 
genetic diagnosis cycles in translocation carriers.
#  Preimplantation genetic diagnosis  # 
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應用在染色體易位攜帶者中胚胎植入前遺傳學診
斷的熒光原位雜交和基因晶片檢測比較
李芷茵、鄒鳳翔、劉綺蘭、楊樹標、何柏松、吳鴻裕
目的：在染色體易位攜帶者胚胎植入前遺傳學診斷（PGD）中，比較
熒光原位雜交（FISH）和基因晶片檢測（aCGH）的妊娠率。
設計：歷史隊列研究。
安排：香港一所教學醫院。
患者：從2001年至2013年為染色體易位攜帶者PGD的治療週期。
結果：研究了共101個PGD治療週期，包括77個週期相互易位和24個
週期羅伯遜易位。FISH和aCGH分別在78和11週期使用。aCGH後
每啟動週期的懷孕率比FISH顯著為高（36.4%比9.0%，P=0.010）。
流產率則沒有顯著分別。邏輯回歸分析證實FISH或aCGH測試方法是
唯一顯著影響懷孕率的因素（比數比=1.875，P=0.023，95%置信區
間：1.090-3.226）。
結論：此本地回顧研究證實，在染色體易位攜帶者PGD治療週期使用
aCGH後的懷孕率顯著高於FISH，因此以後在染色體易位攜帶者PGD
治療週期中，不應再使用FISH而應選擇使用aCGH。
 However, FISH itself carries technical 
difficulties of fixation and spreading of nucleus, 
with the reported error rate of 7% to 10%.4-6 Another 
problem is that in translocation carriers, there is 
interchromosomal effect so that the proportion of 
embryos having aneuploidies is higher than those 
without translocations.7 Segmental loss or gain is also 
a frequent event in human embryos.8,9 Fluorescent 
in-situ hybridisation would not be able to detect 
these chromosomal abnormalities, which could be 
the cause of low success rates of PGD in translocation 
carriers as most of these embryos would result in 
implantation failure or miscarriages.10 
 With the development of comparative 
genomic hybridisation (CGH), it is possible to 
detect abnormalities in all 24 chromosomes and 
its application on single blastomere biopsy was 
first reported in 1996.11 Comparative genomic 
hybridisation is a DNA-based technique, employing 
comparative hybridisation of differentially labelled 
DNA samples to normal metaphase chromosome on 
a microscope slide.4 The ratio of fluorescence reveals 
the gain or loss of the tested samples. However, 
the turnover time is about 4 days, which does not 
fit into the strict time frame of treatment for PGD, 
and cryopreservation of embryos is mandatory, 
unless polar body biopsy is used.12 Array CGH 
(aCGH), employing DNA probes affixed directly 
to a microscope slide, solves this problem as the 
turnover time is about a day, which makes fresh 
transfer after blastomere biopsy or trophectoderm 
biopsy possible.13 It has been demonstrated that 
using aCGH in translocation carriers is beneficial.9 
 Our centre used the FISH technique for 
translocation carriers since our team developed the 
technique of PGD in 2001 which resulted in the first 
live-birth in Hong Kong.14 We acquired the platform 
of aCGH in April 2012. This retrospective analysis 
aimed to compare the pregnancy outcomes using 
FISH and aCGH for the treatment cycles of PGD in 
translocation carriers.
Methods 
Study population
Data from all treatment cycles performed  for PGD 
in the Department of Obstetrics and Gynaecology, 
Queen Mary Hospital/The University of Hong 
Kong from 2001 till 2013 June were retrieved. Only 
PGD cycles in translocation carriers were included 
in the present study, which was approved by the 
Institutional Review Board of the University of Hong 
Kong/Hospital Authority Hong Kong West Cluster.
Treatment regimen
The details of the long protocol of ovarian stimulation 
regimen, gamete handling, cryopreservation of 
embryos, and frozen embryo transfer have been 
previously described.15 The details of PGD have 
also been previously described.16 In short, embryo 
biopsy was performed on day 3 at 6-to-8-cell stage. 
Two blastomeres were tested from 2001 to 2005 
and one blastomere was routinely tested from 2006 
onwards. The blastomere was fixed for FISH analysis. 
Commercially available FISH probes were chosen to 
flank the break point. For aCGH, the blastomere was 
transferred into a polymerase chain reaction tube 
and whole genome amplification was performed 
(SurePlex; BlueGnome, Cambridge, UK). Array 
CGH was performed using 24sure V3 (BlueGnome) 
for Robertsonian translocation carrier or 24sure+ 
(BlueGnome) for reciprocal translocation carrier. All 
results were interpreted separately by two laboratory 
staff.
Outcome measures
The primary outcome measures of the study were 
clinical and ongoing pregnancy rates. Clinical 
pregnancies were defined by the presence of 
one or more gestation sacs or the histological 
confirmation of gestational product in case of early 
pregnancy failures. Ongoing pregnancies were those 
pregnancies beyond 8 to 10 weeks of gestation, at 
which stage the patients were referred for antenatal 
care. The secondary outcome measures were 
miscarriage rate and cancellation rate. Cancellation 
rate was defined as the percentage of treatment 
cycles with no embryo transfer after oocyte retrieval. 
Statistical analysis
The Kolmogorov-Smirnov test was used to test 
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the normal distribution of continuous variables. 
Results of continuous variables were expressed as 
mean ± standard deviation if normally distributed, 
and median (range) if not normally distributed. 
Statistical comparison was carried out by Student’s t 
test, Mann-Whitney U test, and/or Wilcoxon signed 
rank test for continuous variables and Chi squared 
test or Fisher’s exact test for categorical variables, 
as appropriate. Statistical analysis was performed 
using the Statistical Package for the Social Sciences 
(Windows version 20.0; SPSS Inc, Chicago [IL], 
US). The two-tailed value of P<0.05 was considered 
statistically significant. Binary logistic regression 
using enter method was used to calculate the 
prediction of the pregnancy rate in PGD cycles.
Results 
There were 339 PGD cycles, of which 101 treatment 
cycles were performed in translocation carriers 
during the study period: 77 cycles for reciprocal 
translocation and 24 cycles for Robertsonian 
translocation. The two techniques, FISH and aCGH, 
were used in 78 and 11 cycles, respectively (Table 
1). The overall cancellation rate was 39.6% (40/101). 
Four cycles were cancelled due to high risk of ovarian 
hyperstimulation syndrome; eight cycles due to poor 
ovarian responses or poor embryo qualities; and 28 
cycles due to no normal embryo after PGD with 
either technique (Table 1). The cancellation rate 
using FISH technique due to abnormal signals for 
all embryos was significantly higher than that using 
aCGH (34.6% vs 9.1%, respectively). 
 The demographic and clinical data of women 
who underwent PGD with FISH and aCGH are 
presented in Table 2. Women in the aCGH group 
were significantly younger than those in the FISH 
group, and the serum oestradiol concentration 
on ovulation trigger day in the aCGH group was 
significantly higher than that in the FISH group. The 
total dosage of gonadotropin, the number of follicles 
larger than or equal to 16 mm, and the number of 
oocytes retrieved were comparable between the 
two groups. The demographic and clinical data of 
cycles for couples with reciprocal and Robertsonian 
translocation were all comparable (data not shown). 
TABLE 1.  Information on preimplantation genetic diagnosis cycles
Reciprocal translocation Robertsonian translocation Total
PGD for translocations 38 Couples 
77 Cycles
13 Couples 
24 Cycles
51 Couples 
101 Cycles
Technique used 
FISH 57 Cycles 21 Cycles 78/101 (77.2%)
aCGH 9 Cycles 2 Cycles 11/101 (10.9%)
Cancelled cycles 40/101 (39.6%)
FISH (no normal embryo) 27/78 (34.6%)
aCGH (no normal embryo) 1/11 (9.1%)
Poor ovarian response* 8 (7.9%)
OHSS risk 4 (4.0%)
Abbreviations: aCGH = array comparative genomic hybridisation; FISH = fluorescent in-situ hybridisation; OHSS = ovarian 
hyperstimulation syndrome; PGD = preimplantation genetic diagnosis
* One cycle cancelled after PGD due to no blastocyst development, 2 cycles cancelled due to poor embryo quality not suitable for 
PGD, and 5 cycles cancelled with cryopreservation of embryos for next cycle of PGD due to small number of embryos available
Abbreviations: aCGH = array comparative genomic hybridisation; FISH = fluorescent in-situ hybridisation; hCG = human chorionic 
gonadotropin
TABLE 2.  Demographic and clinical data of subjects included in treatment cycles for preimplantation genetic diagnosis using 
fluorescent in-situ hybridisation and array comparative genomic hybridisation
Demographic/clinical data Mean ± standard deviation (range) P value
FISH aCGH
Women's age (years) 34.7 ± 3.1 (28-40) 32.1 ± 3.64 (28-38) 0.026
Total dosage of gonadotropin used (IU) 2364 ± 769 (1175-4200) 2281 ± 955 (1200-3825) 0.583
No. of follicles ≥16 mm 8.0 ± 2.7 (2-15) 9.9 ± 4.2 (5-19) 0.213
No. of oocytes 13.3 ± 7.3 (1-42) 16.7 ± 6.4 (9-28) 0.077
Oestradiol concentration on hCG day (pmol/L) 13 686 ± 5744 (831-26 413) 18471 ± 5632 (10 596-30 067) 0.015
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 The pregnancy rates per cycle and per transfer 
were all significantly higher in cycles performed 
using aCGH. The miscarriage rates were similar 
between the two groups (Table 3). A subgroup 
analysis of cycles performed from 2006 to 2013 
showed similar results in all the above comparisons 
with significantly higher clinical and ongoing 
pregnancy rates per initiated cycle and per transfer 
in cycles using aCGH than those using FISH, but 
with comparable miscarriage rates (data not shown). 
Figures 1 and 2 show PGD results with FISH and 
aCGH, respectively.
 Logistic regression revealed that the method 
of testing (FISH or aCGH) was the only factor that 
significantly affected the ongoing pregnancy rate; 
age of the women, the type of translocation, or other 
clinical information including number of oocytes 
retrieved, the gonadotropin dosage used, and the 
oestradiol concentration on the day of human 
chorionic gonadotropin administration did not 
affect the outcome. The method of testing remained 
a significant factor after controlling for the age of 
TABLE 3.  Pregnancy rates
FISH aCGH P value
Clinical pregnancy rate/initiated cycle 11/78 (14.1%) 6/11 (54.5%) 0.001
Ongoing pregnancy rate/initiated cycle 7/78 (9.0%) 4/11 (36.4%) 0.010
Clinical pregnancy rate/embryo transfer 11/51 (21.6%) 6/10 (60.0%) 0.013
Ongoing pregnancy rate/embryo transfer 7/51 (13.7%) 4/10 (40.0%) 0.048
Miscarriage rate 4/11 (36.4%) 2/6 (33.3%) 0.901
Abbreviations: aCGH = array comparative genomic hybridisation; FISH = fluorescent in-situ hybridization
13 13
13
13
21
21
21
21
21 1313
FIG 1.  Preimplantation genetic diagnosis by fluorescent in-situ hybridisation
Embryo #20  Normal Embryo #21  Normal Embryo #27  Monosomy 21
FIG 2.  Results of array comparative genomic hybridisation (aCGH)
No aneuploidy detected on aCGH (46,XY) 47,XY,+21 (Abnormal embryo with trisomy 21)
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women and type of translocation (Table 4).
 Figure 3 shows the results of aCGH in 
embryos produced from reciprocal translocation 
carrier. Array CGH can detect segmental changes in 
translocated chromosomes (embryo 18) and other 
chromosomes (embryo 3). It can also detect whole 
chromosome aneuploidy (embryo 16). Embryo 7 was 
replaced and resulted in an ongoing pregnancy.
Discussion
The present study showed that PGD using aCGH was 
associated with significantly higher pregnancy rates 
(both per initiated cycle or per embryo transfer) 
versus FISH. The testing method, ie using aCGH or 
FISH, was the only significant factor affecting the 
ongoing pregnancy rate in logistic regression.
 Couples carrying balanced reciprocal or 
Robertsonian translocations are well-known to 
produce a high percentage of unbalanced gametes 
and embryos,17 resulting in high miscarriage rates 
and a variable chance of unbalanced offspring 
with multiple congenital anomalies and mental 
retardation.18 The high percentage of unbalanced 
FIG 3.  Array comparative genomic hybridisation (CGH) of embryo biopsy
The mother was a reciprocal translocation carrier, 46,XX,t(3;4)(q29;q32). Array CGH could detect segmental changes unrelated to translocation 
chromosomes (embryo 3), whole chromosome aneuploidy (embryo 16), and unbalanced reciprocal translocation (embryo 18)
Abbreviations: aCGH = array comparative genomic hybridisation; CI = confidence interval; FISH = fluorescent in-situ hybridisation; hCG = human chorionic 
gonadotropin; OR = odds ratio; PGD = preimplantation genetic diagnosis
TABLE 4.  Logistic regression of variables associated with ongoing pregnancy rate for PGD in translocation carriers
Embryo 3
46,XY,del(1q),del(9q21.11-qter)
Embryo 18
46,XX,dup(3q29-qter) 
del(4q32.2-qter)
Embryo 16
45,XY,-22
Embryo 7
Female 
Normal or balanced translocation carrier
Logistic regression Multivariate regression
B OR P value 95% CI B OR P value 95% CI
Age (years) -0.086 0.917 0.384 0.756-1.114 0.040 1.041 0.772 0.795-1.362
Type of translocation 0.162 1.176 0.084 0.978-1.414 0.096 1.199 0.096 0.969-1.483
Method of PGD (FISH or aCGH) 0.586 1.796 0.018 1.107-2.916 0.745 1.875 0.023 1.090-3.226
No. of oocytes retrieved 0.028 1.028 0.512 0.946-1.118 0.066 1.069 0.302 0.942-1.212
Total gonadotropin dosage -0.070 0.933 0.138 0.851-1.023 -0.031 0.969 0.616 0.858-1.095
Oestradiol concentration on hCG day -0.013 0.987 0.779 0.898-1.084 -0.083 0.920 0.296 0.788-1.075
#  Preimplantation genetic diagnosis  # 
21Hong Kong Med J  ⎥  Volume 21 Number 1  ⎥  February 2015  ⎥  www.hkmj.org
gametes can be explained by the segregation modes 
and behaviours of translocations during meiosis.19 
Not only the direct effect of the translocations on the 
meiosis, but also the interchromosomal effect exerted 
by the translocations increases the percentage of 
aneuploidies in the gametes and embryos of couples 
carrying translocations.7,20-22 It further decreases 
the number of normal/balanced euploid embryos, 
including those suitable and feasible for transfer. It 
was reported that only up to 16% of preimplantation 
embryos were normal/balanced and euploid in 
translocation carriers.9 
 In the past decade, FISH was commonly 
employed to detect the unbalanced chromosome 
rearrangement of embryos using probes depending 
on the translocated segments.23 Fluorescent 
in-situ hybridisation is technically challenging, 
especially with regard to fixation and spreading.3,5,24 
The error rate of FISH was reported to be up to 
10%.5,6,25 As PGD using FISH in translocation 
carriers only employs fluorescent DNA probes 
for the translocated segments, aneuploidies and 
segmental rearrangements which are not related to 
the translocated segments will be missed.3 Even in 
aneuploidy screening, only up to five chromosomes 
can be tested in one round of FISH, and so, usually 
up to half of all chromosomes can be tested in 
repeated rounds. However, repeated rounds were 
related to the decrease in diagnostic accuracy.4 
Therefore, using FISH would miss a proportion of 
aneuploidies and abnormal embryos, which may 
result in misdiagnosis, implantation failure, or 
miscarriages.10 This is probably the major reason for 
the unfavourable results in a systematic review on the 
use of PGD in translocation carriers26 and the meta-
analysis of preimplantation genetic screening.27 The 
cancellation rate, ie no embryo transfer after oocyte 
retrieval, was higher after FISH than that after 
aCGH, probably due to technical difficulties.
 The development of CGH makes it possible to 
test for all 24 chromosomes, while the development 
of aCGH makes it feasible to use the technique in 
the restricted time frame of PGD. Several groups 
of investigators have reported success with using 
aCGH for PGD in translocation carrier couples to 
improve their reproductive outcomes9,28; we have 
shown similar results in this local study.
 Figure 3 shows the result of PGD in a patient 
with reciprocal translocation. Array CGH detected 
unbalanced reciprocal translocated segments in 
embryo 18. It also picked other segmental changes 
(1q and 9q21.11-qter) not related to translocated 
chromosomes in embryo 3. It could also detect 
whole chromosome aneuploidy (monosomy 
22) in embryo 16. In FISH, probes flanking the 
translocation breakpoints are used and, therefore, the 
abnormalities in embryo 3 and embryo 16 cannot be 
detected. Furthermore, the average probe density of 
aCGH used for Robertsonian translocation is 10 Mb 
while that of one used for reciprocal translocation is 
5 Mb. Increase in resolution allows us to easily pick a 
small abnormality in the embryo. Array CGH offers 
a more comprehensive way of PGD in translocation 
carriers and this results in a significant increase in 
the pregnancy rate compared with FISH.
 In our cohort, the age of women for whom 
aCGH was employed was younger than that of 
women for whom FISH was employed. This can 
probably explain the higher oestradiol concentration 
after ovarian stimulation of in-vitro fertilisation 
treatment, along with the non-significant, higher 
number of follicles and oocytes retrieved in the 
aCGH group. In order to reveal the effect of the 
testing method on pregnancy rate, we controlled 
the women’s age, type of translocation, and other 
data of the stimulation including the total dosage of 
gonadotropin and number of oocytes retrieved in 
multivariate logistic regression; the testing method 
remained the only significant factor affecting the 
ongoing pregnancy rate. This indicates that, after 
controlling for all the possible confounding factors, 
PGD cycles using aCGH were associated with a 
significantly higher ongoing pregnancy rate than 
those using FISH.
 It has been controversial whether PGD can 
improve the reproductive outcomes compared 
with natural conception in translocation carriers. 
A systematic review reported adverse effects on the 
pregnancy rates after PGD in translocation carriers 
compared with natural conception.26 However, all the 
PGD cycles included in this review were performed 
with FISH. Moreover, the case reports and case series 
of PGD included had a small number of subjects; in 
16 out of 21 studies, the sample size was only one 
to three cases. Larger systematic reviews on the use 
of aCGH in translocation carriers are urgently 
needed.
 This study is retrospective in nature and there 
may be some confounding factors such as differences 
in embryo biopsy techniques and culture conditions 
which were not controlled for and which might have 
affected the pregnancy outcomes. As we started 
using aCGH approximately one and a half year ago, 
the number of cases was smaller than that using 
FISH. Despite the small sample size, the ongoing 
pregnancy rate revealed a significant increase after 
employing aCGH in translocation carriers. This 
serves to further strengthen our argument in favour 
of PGD programme using aCGH. 
 It is well known that two-blastomere biopsy is 
more detrimental to pregnancy than one-blastomere 
biopsy.22 Our team employed two-blastomere biopsy 
when we first developed our PGD programme. We 
then switched to one-blastomere biopsy in 2006. 
Therefore, a subgroup analysis was performed on 
those cycles between 2006 and 2013. The ongoing 
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pregnancy rate per initiated cycle remained 
significantly higher in the group using aCGH than 
that using FISH. 
Conclusion
Use of aCGH can improve the pregnancy outcomes 
of PGD in translocation carriers compared with 
FISH. Array CGH should be the technique of choice 
for PGD in translocation carriers.
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